Premium
Depo‐medroxyprogesterone in Women on Antiretroviral Therapy: Effective Contraception and Lack of Clinically Significant Interactions
Author(s) -
Cohn S E,
Park JG,
Watts D H,
Stek A,
Hitti J,
Clax P A,
Yu S,
Lertora J J L
Publication year - 2007
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/sj.clpt.6100040
Subject(s) - nevirapine , efavirenz , nelfinavir , medroxyprogesterone acetate , medicine , pharmacokinetics , dosing , medroxyprogesterone , reverse transcriptase inhibitor , pharmacology , gynecology , human immunodeficiency virus (hiv) , antiretroviral therapy , viral load , estrogen , immunology
We conducted an open‐label, steady‐state pharmacokinetic (PK) study of drug interactions among HIV‐infected women treated with depo‐medroxyprogesterone acetate (DMPA) while on nucleoside analogues plus nelfinavir ( N =21), efavirenz ( N =17), or nevirapine ( N =16); or nucleosides only or no antiretroviral therapy as a control group ( N =16). PK parameters were estimated using non‐compartmental analysis, with between‐group comparisons of medroxyprogesterone acetate (MPA) PKs and within‐subject comparisons of ARV PKs before and 4 weeks after DMPA dosing. Plasma progesterone levels were measured at baseline and at 2, 4, 6, 8, 10, and 12 weeks after DMPA dosing. There were no significant changes in MPA area under the concentration curve, peak or trough concentrations, or apparent clearance in the nelfinavir, efavirenz, or nevirapine groups compared to the control group. Minor changes in nelfinavir and nevirapine drug exposure were seen after DMPA, but were not considered clinically significant. Suppression of ovulation was maintained. Clinical Pharmacology & Therapeutics (2007) 81 , 222–227. doi: 10.1038/sj.clpt.6100040 ; published online 27 December 2006